Jurisdiction - Hong Kong
Kirkland & Ellis Represents China Traditional Chinese Medicine In Its Acquisition of 81.48% Of Jiangyin Tianjiang Pharmaceutical.

28 January, 2015


Kirkland & Ellis is acting for Hong Kong-listed China Traditional Chinese Medicine Co. Limited in its proposed USD 1.34bn acquisition of a 81.48% stake in Jiangyin Tianjiang Pharmaceutical Co. Ltd., the largest manufacturer of concentrated traditional Chinese medicine granules in China, from seven sellers including, among others, two CICC-affiliated funds, Shanghai-listed Shanghai Jiahua United Co., Ltd. and Shanghai-listed Guangdong Keda Clean Energy Co., Ltd..


The Kirkland team is led by Hong Kong-based corporate partner Frank Sun, and includes corporate partners David Yun and Joey Chau.


Conventus Law

Follow us on Twitter @conventuslaw

Comments are closed.